This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bipolar Disorder  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with great interest the article by Tohen et al¹ "Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression." We also attended a presentation at the 2003 American Psychiatric Association Annual Meeting² when the same study was presented and notice rather strangely that the remission rates of the study on both occasions were different even though the study population was the same. At the American Psychiatric Association meeting, the remission rates quoted were placebo, 29.1%; olanzapine, 40.5%; and olanzapine-fluoxetine combination, 56.3%. On the other hand, in the November article, the rates quoted were placebo, 24.5%; olanzapine, 32.8%; and olanzapine-fluoxetine combination, 48.8%. Could the authors please explain the reason(s) for the disparities?

From a methodological viewpoint, the design of the study could be faulted on the basis of being an incomplete factorial design. The addition of a fluoxetine monotherapy arm would have completed the design.

AUTHOR INFORMATION
Correspondence: . . . [Full Text of this Article]

A. B. Williams, MD, MRCPsych; B. A. Adetunji, MD, MSc

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?